EGFR mutations are divided into seven levels, depending on the clinical targeted therapy implication, with mutations included in level 1 and R1 indicated as targetable, according to Food and Drug Administration.91,92 All level 1 mutations are detected in NSCLC – 28 mutations in LUAD and 2 in lung squamous cell carcinoma and concentrated in exons 19-21 - L858R, L861Q, G719A, S768I, L833F, E796_A750del, L747_E749del, E709_T710delinsD, L747_T751del, and T751_E758del.90 This evidence concerns the gene EGFR and non-small cell lung carcinoma.